NCT01919879View on ClinicalTrials.gov

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2017

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab + Afatinib

Afatinib taken orally, cetuximab administered intravenously

DRUG

Cetuximab

Cetuximab administered intravenously

Trial Locations (1)

44805

Institute de Cancérologie de la Loire, Nantes

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01919879 - Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter